Search research articles

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Stereotactic radiosurgery and multimodal integration approaches for germ cell tumor brain relapse.

Journal of neuro-oncology·2026

Same author

Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States.

Cancer medicine·2026

Same author

How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

Same author

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

EClinicalMedicine·2026

Same author

Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Association of Y-chromosomal gr/gr deletions with testicular germ cell tumor: whole-genome analysis of 198,306 individuals.

medRxiv : the preprint server for health sciences·2026

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 24, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy.

Victoria A Sanchez¹, Paul C Dinh², Patrick O Monahan³

¹Department of Otolaryngology-Head and Neck Surgery, University of South Florida, Tampa.

|June 6, 2024

Summary

This summary is machine-generated.

Cisplatin-related hearing loss (CRHL) is common in cancer survivors, with progression linked to cumulative dose and hypercholesterolemia. Regular audiological assessments and hypercholesterolemia management are crucial for managing hearing in survivors.

More Related Videos

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: Jun 24, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Ototoxicity and audiology
Cancer survivorship
Longitudinal health outcomes

Background:

Cisplatin is a widely used chemotherapy agent known for its ototoxicity.
Limited data exists on cisplatin-related hearing loss (CRHL) progression in adult cancer survivors using comprehensive audiologic assessments.
Understanding risk factors and longitudinal changes is crucial for managing hearing health in this population.

Purpose of the Study:

To assess CRHL using comprehensive audiologic tests, including Words-in-Noise (WIN).
To evaluate the longitudinal progression of CRHL.
To identify risk factors associated with CRHL and its progression.

Main Methods:

A longitudinal study of 100 cisplatin-treated testicular cancer survivors (TCS) with ongoing follow-up.
Comprehensive audiologic assessments including full-spectrum audiometry and WIN tests.
Multivariable analyses to identify factors associated with hearing loss and its progression.

Main Results:

78% of TCS showed audiometrically defined hearing loss at follow-up, with self-reported hearing loss correlating with worse outcomes.
Poorer WIN performance was linked to hypercholesterolemia, lower education, and hearing loss severity.
CRHL progression was associated with hypercholesterolemia and increasing age, with a significant interaction with cumulative cisplatin dose (>300 mg/m2).

Conclusions:

Strict hypercholesterolemia control and regular audiological assessments are recommended for cisplatin-treated survivors.
Risk stratification should incorporate hearing concerns.
CRHL progression is associated with cumulative cisplatin dose, warranting further long-term investigation.